GlassScriptPhysician profile
Raetasha Dabney
NPI 1124219449
$8,662.21
in general payments reported to CMS, 2019-2025
53 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.11 · 2020: $583 · 2021: $1,735 · 2022: $1,518 · 2023: $712 · 2024: $1,344 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560 · Long Term Medical Supply Or Device Loan: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,559.73 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $3,294.78 | 2021-2024 | Endopredict, Myrisk |
| Novartis Pharmaceuticals Corporation | $1,345.48 | 2022-2025 | |
| Celgene Corporation | $382.61 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $334.53 | 2020-2025 | Enhertu |
| Daiichi Sankyo INC. | $274.49 | 2020-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $241.23 | 2020-2025 | |
| Abbvie INC. | $230.48 | 2023-2025 | Venclexta, Lupron Depot |
| Gilead Sciences, INC. | $229.09 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $222.32 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $204.53 | 2020-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $160.72 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $113.11 | 2020-2025 | |
| Glaxosmithkline, LLC. | $107.97 | 2024-2025 | Jemperli, Ojjaara |
| Incyte Corporation | $106.18 | 2020-2025 | Monjuvi, Jakafi |
| Eisai INC. | $103.43 | 2023-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raetasha Dabney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.